Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP395 DDI Study with Verapamil, Midazolam, and Digoxin
NCT06118684Phase 1Completed
- Sponsor
- EpiEndo Pharmaceuticals
- Start
- Oct 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of glasmacinal in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by EpiEndo Pharmaceuticals. Primary endpoints: Pharmacokinetic parameters of EP395 (AUC, Cmax, Tmax, T1/2, CL/F, Vz/F) and Pharmacokinetic parameters of midazolam and digoxin (AUC, Cmax, Tmax, T1/2). Started Oct 2023; status: completed.
02
Drugs
glasmacinal
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT06118684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06118684.